| name | tooluniverse-precision-oncology |
| description | Cancer treatment recommendations from molecular profile (mutations + cancer type + biomarkers) โ FDA-approved + investigational therapies, resistance mechanisms, matching clinical trials, prognosis. Uses CIViC, ClinVar, OpenTargets, ClinicalTrials.gov. Use for tumor-board treatment recommendations, evidence-tiered actionability assessment, and FDA-precedent-driven therapy selection. |
Precision Oncology Treatment Advisor
Provide actionable treatment recommendations for cancer patients based on their molecular profile using CIViC, ClinVar, OpenTargets, ClinicalTrials.gov, and structure-based analysis.
Domain Reasoning
Treatment selection follows a strict evidence hierarchy: FDA-approved for this specific mutation in this cancer type ranks highest, followed by approval for this mutation in any cancer (tumor-agnostic), then active clinical trials, and finally off-label use. Skipping this hierarchy to recommend off-label therapies when an approved option exists is a clinical error. Always check current NCCN guidelines and recent literature, as approvals change rapidly โ a drug that was investigational last year may now be first-line.
When looking up treatment for a specific mutation, search CIViC and OncoKB FIRST, not PubMed. These databases have curated evidence levels. PubMed is for when curated databases don't have the answer.
Treatment Selection Reasoning
Biomarker-to-drug logic โ When a biomarker is identified, the first-line targeted therapy follows established mappings. Always verify current approval status via OncoKB/CIViC, but use this as a starting framework:
- NSCLC: EGFR exon 19 del / L858R โ osimertinib (1L); ALK fusion โ alectinib/lorlatinib; ROS1 fusion โ crizotinib/entrectinib; KRAS G12C โ sotorasib/adagrasib; MET exon 14 skip โ capmatinib/tepotinib; RET fusion โ selpercatinib; BRAF V600E โ dabrafenib+trametinib; NTRK fusion โ larotrectinib/entrectinib (tumor-agnostic)
- Breast: HER2+ โ trastuzumab+pertuzumab (1L), T-DXd (2L); HR+/HER2- โ CDK4/6i (palbociclib/ribociclib) + AI; BRCA1/2 mut โ olaparib/talazoparib; PIK3CA mut โ alpelisib+fulvestrant
